Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905956 | 1.00 | NR1I2 (0.54) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL10597149 | 0.95 | ALDH1A1 (0.56) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL9905966 | 0.95 | ALDH1A1 (0.56) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL16140067 | 0.95 | ALDH1A1 (0.56) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL9905964 | 0.93 | NR1I2 (0.44) | NR1I2PGRADORA3PTGS2PDE4D | |
| SCHEMBL24625000 | 0.89 | LPAR1 (0.53) | — | |
| SCHEMBL9905957 | 0.87 | LPAR1 (0.47) | — | |
| SCHEMBL11086686 | 0.85 | LPAR1 (0.56) | — | |
| SCHEMBL16636964 | 0.85 | LPAR1 (0.56) | — | |
| SCHEMBL30257188 | 0.82 | LPAR1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LTD (IN) | 2022-02-17 | — | — | US | disclosed |
| US-10774059-B2 | Compositions and methods for the treatment of inflammation | CELLIX BIO PRIVATE LIMITED (IN) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IL1B, IL36G, IL17A | NR1I2 538/4885PGR 1809/4885ADORA3 1633/4885 |
| US-10774059-B2 | Compositions and methods for the treatment of inflammation | IL1B, IL36G, IL17A | NR1I2 538/4885PGR 1809/4885ADORA3 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.